American biotechnology company at Lexington in Massachusetts, formed in 2000 from the merger of Creative Biomolecules, Ontogeny and Reprogenesis and listed on the Nasdaq. Develops targeted small molecule medicines for cancer, with emavusertib, an inhibitor of the IRAK4 kinase, in trials in blood cancers and lymphoma, and earns royalties on vismodegib, the hedgehog pathway inhibitor sold as Erivedge which came out of its research and is partnered with Genentech.
No comments available.
Leave your rating & comment